重组人脑利钠肽和米力农治疗慢性心衰急性发作期的效果比较

目的 探讨慢性心衰急性发作期患者应用重组人脑利钠肽与米力农治疗的临床效果。方法 选取2017年8月～2019年8月在我院接受治疗的40例慢性心衰急性发作期患者进行分组研究,随机分为观察组(n=20)与对照组(n=20)。观察组给予重组人脑利钠肽治疗,对照组给予米力农治疗,对比两组临床疗效、治疗前后各指标[心功能、脑利钠肽(BNP)、去甲肾上腺素(NE)]水平及不良反应发生率。结果 观察组临床总有效率为95.00%,对照组为70.00%,观察组显著高于对照组(P0.05)。观察组治疗后左心室舒张末期内径(LVEDD)显著小于对照组,左室射血分数(LVEF)显著大于对照组(P0.05)。观察组治疗后BNP、NE水平显著低于对照组(P0.05)。观察组不良反应发生率为5.00%,对照组为30.00%,观察组显著低于对照组(P0.05)。结论 慢性心衰急性发作期患者应用重组人脑利钠肽治疗的临床效果显著优于米力农,可进一步改善患者心功能,且具有较高的安全性,值得临床应用推广。

Comparison of effects of recombinant human brain natriuretic peptide and milrinone in treatment of acute attack of chronic heart failure

Objective To compare the clinical effects of recombinant human brain natriuretic peptide and milrinone in patients with acute attack of chronic heart failure.Methods Forty patients with acute attack of chronic heart failure who were treated in our hospital from August 2017 to August 2019 were randomly divided into the observation group(n=20) and the control group (n=20).The observation group were treated with recombinant human brain natriuretic peptide,and the control group were treated with milrinone.The clinical efficacy,the indicator levels before and after treatment,including heart function,brain natriuretic peptide (BNP) and norepinephrine (NE),and the incidences of adverse reactions of the two groups were compared.Results The total effective rate was 95.00% in the observation group and 70.00% in the control group.The total effective rate in the observation group was significantly higher than that in the control group(P<0.05).The left ventricular end-diastolic diameter (LVEDD) was significantly lower in the observation group than that in the control group,and the left ventricular ejection fraction(LVEF)in the observation group was significantly higher than that in the control group(P<0.05).The levels of BNP and NE in the observation group after treatment were significantly lower than those in the control group (P<0.05).The incidence of adverse reactions was 5.00% in the observation group and 30.00% in the control group.The incidence of adverse events in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The clinical effect of recombinant human brain natriuretic peptide in patients with acute attack of chronic heart failure is significantly better than that of milrinone.Recombinant human brain natriuretic peptide can further improve the heart function of patients,with high safety.It is worth to be popularized in clinical practice.